FDA Approves Corcept’s Selective Glucocorticoid Receptor Modulator
The Food and Drug Administration (FDA) has approved Corcept Therapeutics’ relacorilant, a selective glucocorticoid receptor (GR) modulator, for utilize in combination with standard chemotherapy for adult patients with platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Corcept News Release
Understanding Relacorilant and its Mechanism
Relacorilant is designed to block the GR, a protein involved in several physiological processes, including the body’s response to stress and immune function. In cancer, the GR can contribute to chemotherapy resistance. By selectively modulating the GR, relacorilant aims to enhance the sensitivity of cancer cells to platinum-based chemotherapy drugs, even in cases where the cancer has developed resistance.
Clinical Trial Results
The approval is based on data from the Phase 3 ROCKET trial, which demonstrated that relacorilant, in combination with paclitaxel, significantly improved progression-free survival (PFS) in patients with platinum-resistant ovarian cancer. The trial involved patients whose cancer had stopped responding to platinum-based chemotherapy, a common challenge in ovarian cancer treatment.
What This Means for Patients
For patients with platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, relacorilant offers a new treatment option. The combination therapy aims to overcome chemotherapy resistance and potentially extend the time before the cancer progresses.
Potential Side Effects
As with any cancer treatment, relacorilant can cause side effects. Common side effects observed in clinical trials included fatigue, nausea, and decreased appetite. Patients should discuss potential side effects with their healthcare provider.
Looking Ahead
Corcept Therapeutics is continuing to investigate relacorilant in other cancer types and combinations. The approval of relacorilant marks a significant step forward in the development of targeted therapies for ovarian cancer and highlights the potential of GR modulation as a strategy to overcome chemotherapy resistance.